title: Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.
abstract: BACKGROUND
  How hepatitis B virus (HBV) infection react to hepatocellular carcinoma (HCC) treatment remains unclear, and the roles of anti-HBV therapy were seldom reported in HCC.
  
  
  OBJECTIVE
  To evaluate changes of HBV replication and liver function after hepatectomy or transarterial chemoembolization (TACE) for HCC, also the short-term effects of anti-viral therapy were analyzed.
  
  
  METHODS
  Totally, 590 HBsAg (+) HCC patients were recruited into two groups: only surgical resection, and only TACE, and subgrouped according to anti-HBV therapy or none. Clinical data were analyzed for statistical significance and risk factors for adverse events.
  
  
  RESULTS
  In the no antiviral therapy groups, rates of HBV reactivation were 15.7% and 17.5% in patients who underwent hepatectomy and TACE, respectively, while the rates of deterioration of liver function were 4.1% and 8.1%, respectively. In contrast, in the antivirus group, the rates of reactivation were 0% and 1.5% after hepatectomy and TACE respectively, while the liver function deterioration rates were 2.4% and 1.5%, respectively. For patients who underwent hepatectomy, no antiviral therapy, and long hepatic inflow occlusion times increased the risk of HBV reactivation. For TACE, no antivirus and HBeAg negativity were the risk factors for reactivation. HBV reactivation was significantly correlated to liver function exacerbation after hepatectomy, while HBV reactivation, baseline ALT (alanine aminotransferase), and α-fetoprotein levels were significantly correlated to liver function exacerbation after TACE.
  
  
  CONCLUSIONS
  HBV reactivation can occur after hepatectomy or TACE. Anti-HBV therapy can reduce the risk of reactivation, thus reducing the risk of liver failure especially in patients undergoing TACE.
authors: Department of Hepatobilliary Oncology, Sun Yat-sen University Cancer Center & State Key Laboratory of Oncology in Southern China, Guangzhou, China.
authors: Xiang-Ming
authors: XM
authors: Lao
authors: Guangyu
authors: G
authors: Luo
authors: Liang-Tao
authors: LT
authors: Ye
authors: Cheng
authors: C
authors: Luo
authors: Ming
authors: M
authors: Shi
authors: Dian
authors: D
authors: Wang
authors: Rongping
authors: R
authors: Guo
authors: Minshan
authors: M
authors: Chen
authors: Shengping
authors: S
authors: Li
authors: Xiaojun
authors: X
authors: Lin
authors: Yunfei
authors: Y
authors: Yuan
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000628:therapy* / Q000821:virology; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D016009:Chi-Square Distribution; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects; D006509:Hepatitis B / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006518:Hepatitis Viruses / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development / Q000276:immunology; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy* / Q000821:virology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens